8 results about "Clopidogrel" patented technology

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The disclosure discloses a method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel and a method for determining the same, which belongs to the technical field of pharmaceutical analysis and solves the problem in the prior art that there is not yet a method for determining the concentration of (7aS,2′S)-2-oxo-clopidogrel in plasma. The method for treating a plasma sample containing (7aS,2′S)-2-oxo-clopidogrel comprises: taking whole blood containing (7aS,2′S)-2-oxo-clopidogrel, adding a reducing agent solution and collecting plasma. The method for determining (7aS,2′S)-2-oxo-clopidogrel in plasma according to the disclosure uses the treatment method as described above to treat a sample to be determined, and includes the following steps: S1. Whole blood treatment: taking whole blood, adding a reducing agent solution, centrifuging, and collecting plasma; S2. Plasma sample pre-treatment: adding a protein precipitant and an internal standard working solution to the plasma, vortexing and then centrifuging, and taking the supernatant; S3. LC / MS / MS determination. The method of the disclosure is simple, easy to operate, and has good stability, specificity and sensitivity, and accurate determination results.

The invention discloses a method for producing a clopidogrel intermediate through biological catalysis chiral resolution, which comprises the following steps: screening an esterase mutant capable of efficiently resolving the clopidogrel intermediate (R, S)-2-(2-chlorphenyl)-2-(2-thiophene ethylamino) methyl acetate through molecular modification to obtain (S)-2-(2-chlorphenyl)-2-(2-thiophene ethylamino) methyl acetate; according to the present invention, the biocatalysis activity and the stereoselectivity are high, the reaction efficiency is improved, the position of the biocatalysis step in the whole synthesis route is beneficial to the improvement of the efficiency of other chemical steps, the overall conversion rate, the enantiomer excess value and the product purity, and the production cost can be significantly reduced. In addition, the method also has the common advantages of enzymatic synthesis, such as simplicity and convenience in implementation and operation, greenness and environmental protection, easiness in product separation and the like.

The invention discloses a clopidogrel aspirin tablet and a preparation method thereof, the clopidogrel aspirin tablet is prepared by tabletting an aspirin layer and a clopidogrel layer, the aspirin layer is composed of an aspirin tablet core, two isolation layers and an enteric-coated layer inserted between the two isolation layers, and the dosage of talcum powder is reduced to be less than 40% of the total weight of an enteric-coated material. According to the clopidogrel aspirin tablet and the preparation method thereof, on the premise that the coating process is smooth and free of precipitation and flocculation phenomena, the prepared clopidogrel aspirin tablet has good pressure resistance and acid resistance and good long-term dissolution stability by controlling the selection of a specific plasticizer (preferably polyethylene glycol 400) in the aspirin layer and optimizing the dosage, and the clopidogrel aspirin tablet is equivalent to an original reference preparation.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses a synergistic effect of combined application of Metrnl protein and a clinical first-line therapeutic drug clopidogrel for treating thrombus, and the Metrnl protein has important significance in the field of thrombotic disease treatment. According to the invention, mice are divided into four groups: a solvent control group, a Metrnl proteome, a clopidogrel group and a drug combination group. A FeCl3 induced thrombus experiment shows that thrombus formation can be inhibited by independently using Metrnl protein and clopidogrel, the thrombus formation inhibition effect is stronger by combined medication, and a synergistic effect is achieved. In addition, in the aspect of untoward effects of bleeding, compared with a clopidogrel single drug group, the risk of bleeding of the drug combination group is not obviously increased. The metrnl protein and clopidogrel are combined to enhance the antithrombotic curative effect without increasing the adverse reaction of bleeding, so that the metrnl protein and clopidogrel have good treatment potential and safety.

The application provides a combined drug for improving embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen a general drug combination on the basis of a large heterogeneous RIF population, the application locks 1119 kinds of drugs that may have a therapeutic effect in a large range through a six-step screening method combined with advanced RNA sequencing technology, and then further screens the drugs by using a highly simulated endometrial epithelial organoid and stromal cell model, tests the influence of the 1119 kinds of drugs on the activity of the endometrial epithelial organoid and stromal cell, and finally screens 7 kinds of effective drugs which can form a broad-spectrum drug with significant therapeutic effect on RIF in a combined form. The 7 kinds of effective drugs screened by the application are icotinib, fumaric acid propofol tenofovir tablets, clopidogrel, tizacat, osimertinib, venetoclax and rebastinib.

The invention provides a combined medicine for improving the embryo implantation efficiency of RIF patients and a screening method, and belongs to the technical field of embryo implantation. In order to solve the problem of how to screen general drug combinations on the basis of a huge heterogeneity RIF group, 1119 drugs which possibly have treatment effects are locked in a large range through a six-step screening method in combination with an advanced RNA (Ribonucleic Acid) sequencing technology; the method comprises the following steps: selecting 1119 types of medicines, then further utilizing a highly simulated endometrial epithelium organ and interstitial cell model to screen medicines, testing the influence of the 1119 types of medicines on the activity of the endometrial epithelium organ and interstitial cell, and finally screening 7 types of effective medicines to form a broad-spectrum medicine with a remarkable curative effect on RIF through a combination form. The seven effective drugs screened by the invention are respectively icotinib, a propofol fumarate tenofovir tablet, clopidogrel, tizacarbox, osimertinib, Vinetogram and ribotinib.